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Polyomaviruses induce cell proliferation and transformation through different oncoproteins encoded
within the early region (ER): large T antigen (LT), small T antigen (sT) and, in some cases, additional
components. Each virus utilizes different mechanisms to achieve transformation. For instance, the LTs of
Simian virus 40 (SV40), BK and/or JC virus can induce transformation; but Merkel Cell Polyomavirus
(MCPyV) requires expression of sT. Lymphotropic Papovavirus (LPV) is closely related to Human Poly-
omavirus 9 (HuPyV9) and, under similar conditions, mice expressing LPV.ER exhibit higher rates of tumor
formation than mice expressing SV40.ER. We have investigated the contributions of individual LPV.ER
components to cell transformation. In contrast to SV40, LPV.ER transforms mouse embryonic ﬁbroblasts
(MEFs), but expression of LPV LT is insufﬁcient to transform MEFs. Furthermore, LPV sT induces
immortalization and transformation of MEFs. Thus, in the case of LPV, sT is the main mediator of
oncogenesis.
& 2015 Elsevier Inc. All rights reserved.Introduction
Lymphotropic Papovavirus (LPV) is a primate polyomavirus
originally isolated from the B-lymphoblast cells of African green
monkey (zur Hausen and Gissmann, 1979), and later found to grow
in B-lymphoblast cells of human and primate origin (Takemoto et
al., 1982; Takemoto and Segawa, 1983). About 30% of normal
human adults contain antibodies recognizing LPV or a similar virus
(Takemoto and Segawa, 1983).
LPV is similar to other known polyomaviruses in terms of
genome size, coding potential and genome organization (von
Hoyningen-Huene et al., 1992; Pawlita et al., 1985). Based on
sequence homology of the LT proteins, LPV is a distant relative of
both SV40 and MuPyV, but is closely related to the recently dis-
covered human HuPy9 (Scuda et al., 2011).
The ER from LPV possesses a high capacity of inducing cellular
transformation, both in cell culture and in vivo systems. For
instance, the infection of hamster embryonic cells with LPV
induces anchorage independence and allows the cells to grow in
low serum, and LPV transformed cells are tumorigenic in newbornhamsters (Kang and Folk, 1992; Takemoto and Kanda, 1984). LPV.
ER is also capable of inducing tumorigenesis in transgenic animals
(Chen et al., 1989; Symonds et al., 1991), even to greater extent
than SV40.ER. For instance, transgenic mice expressing either LPV.
ER or SV40.ER under the same promoter show robust neoplastic
growth in the choroid plexus, thymus and spleen, as well as
lymphoproliferative disorders such as lymphoma and leukemia
(Chen et al., 1989); but the LPV.ER transgenic mice show higher
rates of neoplasic formation than those observed in mice expres-
sing SV40.ER (Chen et al., 1989; Chen and Van Dyke, 1991).
The LPV early region has been shown to encode both LT and sT
but, at present, we do not know which LPV.ER-encoded proteins
contribute to tumorigenesis. However, unlike SV40 LT, some
results suggest that LPV LT may not be the essential oncoprotein
mediating transformation. For instance, pools of cells transformed
by SV40.ER express high levels of LT, but cells transformed via LPV.
ER show low LT levels, perhaps because they become genetically
unstable when expressing high LT levels and are thus eliminated
by negative selection (von Hoyningen-Huene et al., 1992). We have
performed an extended analysis of the different T antigen products
encoded by LPV.ER and examined their ability to transform mouse
embryo ﬁbroblasts and found new properties of the T antigens
encoded by LPV.
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LPV.ER immortalizes and transforms primary MEFs in cell culture
We expressed LPV.ER in primary mouse embryonic ﬁbroblasts
(MEFs) under the control of the CMV promoter. For comparison,
we also expressed in parallel the SV40.ER. Two independent pools
of cells expressing each ER were analyzed. Expression of either the
LPV or SV40 ER resulted in morphological transformation (Fig. 1A)
and enhanced proliferation in 10% serum compared to wild type
MEFs (Fig. 1B).
Next, we compared the abilities of LPV.ER and SV40.ER to
induce growth in low serum and growth independent of ancho-
rage. As expected, wt MEFs failed to proliferate in 1% serum,
while expression of ERs from SV40 or LPV induced similar levels
of cell proliferation (Fig. 1C). Similarly, while wt MEFs failed to
proliferate in soft agar and remained as single cells, the expres-
sion of the early region of LPV or SV40 induced colony formation
(Fig. 1D). The soft agar colonies formed by LPV.ER-expressingFig. 1. LPV.ER expression leads to enhanced growth and transformation of MEFs. (A) Equ
were plated in cell culture and allowed to proliferate. Images (original magniﬁcation: 50
SV40 or LPV.ER. Wild-type MEFs or MEFs expressing the SV40.ER or LPV.ER were plated
(C) Growth curve analysis in media containing 1% serum. Wild-type MEFs or MEFs e
supplemented with 1% FBS as described inMaterials and methods. Cells were counted at v
and LPV.ER-expressing MEFs. Cell were suspended in media containing agar supplemente
developed. Images were taken at the same time for all cultures at same magniﬁcation.MEFs were considerably larger than those formed by MEFs
expressing SV40.ER.
LPV.ER encodes four differentially spliced products
Next we examined the mRNAs expressed by the LPV.ER. Total
RNA was extracted from MEFs or human ﬁbroblasts (BJ;hTERT)
expressing LPV.ER and subjected to RT-PCR. We ﬁrst used primers
speciﬁc for the 50 and 30 end of the ER (Set A, Materials and
methods) and detected three viral PCR products (Fig. 2A, upper
panel). The identity of a PCR product showing the expected size for
LPV LT (2094 bp; Fig. 2A and B) was conﬁrmed by DNA sequencing.
A second product, which we named Large T prime (LT0), migrated
around 750 bp (Fig. 2A) and corresponded to a newly identiﬁed
mRNA generated by removal of two introns from the ER-full length
transcript (Fig. 2B). LT0 mRNA utilizes the same splice acceptor and
donor sites as the LT mRNA, and thus includes the complete exon
1 of LT. In addition, a second splice results in exclusion of most of
the remaining exon 2 from LT, though it retains 134 bp from the 30al amounts of wild-type MEFs, MEFs expressing SV40.ER or MEFs expressing LPV.ER
 ) were taken 2–3 days after plating. (B) Growth curve analysis of MEFs expressing
in 6 cm dishes and counted a various times as described in materials and methods.
xpressing the SV40 or LPV ER were plated in 6 cm dishes and grown in media
arious times after plating. (D) Anchorage independent growth of wild type, SV40.ER
d with 10% FBS (Materials and methods), and monitored for 3–4 weeks until colonies
Fig. 2. LPV.ER encodes four differentially spliced products. (A) RT-PCR analysis of MEFs and BJ;hTERT cells expressing LPV.ER. Three bands ampliﬁed with primer set A
(Materials and methods) are shown in the upper panel and correspond to LT (2.1 kb), LT0 (750 bs) and a PCR artifact (1 kb) conﬁrmed by sequencing. Puriﬁed plasmids
were used as controls (not shown). Two bands were ampliﬁed with primer set B (Materials and methods) and are shown in the lower panel, corresponding to sT (550 b) and
its spliced product sT0 (300 b). (B) Schematic diagram of the splicing pattern generating LT, LT0 , sT and sT0 from LPV.ER. The length of the segment in nts is indicated below
each bar, and the vertical round head arrow shows the position of the stop codon for each transcript. Two sets of primers, A and B (Materials and methods), were used to
amplify the different components within LPV.ER and are indicated. (C). Schematic representation of LPV proteins. Protein domains are inferred from sequence homology with
SV40 LT. J indicates the J domain, OBD indicates the origin-binding-domain, Zn indicates the Zn binding domain, and ATPase indicates the ATPase domain. LPV LT contains
similar domains and unstructured regions to SV40 LT, but lacks the C-terminal HR region and possess a longer linker region. LPV LT0 contains a J-domain, linker region and
4 amino acids of the OBD domain, and a unique C-terminus region due to a change in reading frame. LPV sT shares the J-domain with LT and LT0 , but its C-terminus region
contains putative PP2A interaction sites and a histidine–cysteine rich motif. sT0 contains a J domain and a unique C-terminus. N200 is a truncation mutant sharing the J
domain and LxCxE motif with LT and LT0 , but lacking the C-terminus unique region. (D) RT-PCR analysis of MEFs expressing LPV.ER components independently or in
combinations. The upper panel shows detection of LT and LT0 transcripts with primer set A; lower panel shows detection of sT and sT0 transcripts with primer set B.
(E) Western blot analysis of MEFs expressing LPV.ER products independently or in different combinations. Extracts were probed with Xt7 monoclonal antibody, which
recognizes the J domain.
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reading frame and introduces a stop codon 17 bps earlier than the
one observed in LT (Fig. 2B). Therefore, the putative LT0 protein
encoded by this alternative transcript shares the ﬁrst 203 amino
acids with LT, followed by 38 unique amino acids in the carboxy-
terminal region (Fig. 2B and C). We were unable to conﬁrm the
identity of the third ampliﬁed product(s) migrating around 1 kbp
(*, Fig. 2B).
To ensure detection of LPV sT expression by RT-PCR, we then
used primers speciﬁc to the 50 and 30 ends of the LPV sT coding
sequences (Set B,Materials and methods, Fig. 2B), and detected two
distinct products (Fig. 2A, lower panel). An ampliﬁcation product
of approximately 570 bp was sequenced and conﬁrmed to corre-
spond to sT. An additional band of approximately 324 bp, which
we called small T prime (sT0), corresponded to a spliced variant of
the sT transcript. This transcript shares the ﬁrst 273 bp with the sT
transcript, but a unique 246 bp region is removed by splicing(Fig. 2B). The corresponding sT0 protein retains the J-domain but
lacks the PP2A interacting motifs and the metal binding clusters
present in sT (Fig. 2C), and instead contains a unique carboxy-
terminal region.
To rule out possible promoter-speciﬁc effects, we also expres-
sed the LPV.ER under the control of MoMuLV (Mouse Moloney
leukemia virus) promoter. The same splicing pattern was observed
upon expression from CMV or MoMuLV promoter (Fig. 2A and data
not shown).
Next, we cloned the cDNAs of LPV LT, LT0 and sT in retroviral
vectors, and obtained at least two independent MEF pools
expressing each cDNA individually or in different combinations.
Transcript and protein analysis of the MEF pools was subsequently
done by RT-PCR and western blot. Using either primer set A to
amplify LT and LT0 transcripts, or primer set B to detect sT and sT0
transcripts, we observed only the expected products correspond-
ing to each retroviral construct. As the LT0 splicing sites are present
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both LT and LT0 transcripts (Fig. 2D). Similarly, MEFs transduced
with LPV sT contain LPV sT and sT0 transcripts (Fig. 2D). We esti-
mated the sizes of the four LPV early transcripts to be 2449 bp (sT),
2203 bp (ST0), 2094 bp (LT), and 743 bp (LT0). In agreement with
our results, previous studies of human B-lymphoblastoid cells
infected with the LPV virus also suggested the presence of two or
more transcripts encoded by the LPV.ER (Abraham et al., 1984).
Our transcript analysis indicated that all the putative ER pro-
ducts share the N-terminus J-domain. Therefore, we used a
monoclonal antibody (Xt7) speciﬁc for epitopes present within the
J-domain to monitor protein expression in different pools of MEF
cells (Materials and methods). As expected, strong expression of LT
was observed in MEFs after transduction with either LPV.ER, LT or
LT plus sT; LT0 product was present in cells transduced with LPV.ER
or LT0 alone; and sT expression was observed either in MEFs
expressing LPV.ER, sT alone or sT in combination with LT (Fig. 2E).
However, despite containing sT0 transcripts (Fig. 2D), cell pools
expressing neither sT nor LT plus sT showed sT0 protein expression
(Fig. 2E and data not shown). Similar transcript and protein
expression patterns were observed in human ﬁbroblasts (BJ;hTERT
and IMR90) expressing LPV.ER (data not shown).
LPV LT and sT independently induce immortalization and increase cell
proliferation in MEFs
To determine the contributions of different LPV.ER proteins to
immortalization and transformation of MEFs, we analyzed the
properties of each product individually or in different combina-
tions. As expected, MEFs expressing LPV LT alone exhibited very
robust proliferation (Fig. 3A and B). Surprisingly, sT-expressing
MEFs also showed enhanced proliferation (Fig. 3A and B) at rates
comparable to those of cells expressing LT (Fig. 3B). These results
are in clear contrast to observations in MEFs expressing SV40 sT,
whose presence is growth inhibitory and results in cellular
senescence (Fig. 3C).Fig. 3. Different effects of LPV.ER components on cell proliferation. (A) Morphology of ME
was as described previously (Fig. 1A, Materials and methods). (B) Growth curve analys
components were allowed to proliferate in medium supplemented with 10% FBS, and th
point is an average of 2 separate experiments, performed using 2 biological replicates
transduced with retroviruses containing empty vector (MEF) or SV40 sT cDNA (SV40 sT)
Blue-violet positive staining and enlarged morphology were observed only in SV40 sT eIn contrast to wt MEFs, which are primary cells and normally
growth arrest after 6–8 passages in culture, MEFs expressing either
LT or sT continued proliferation for over (420) passages. Finally,
the proliferation rates observed in MEFs upon combined LT and sT
expression were similar to those produced by either LT or sT alone
(Fig. 3B). We conclude that both LPV LT and sT proteins are capable
of inducing immortalization and enhancing proliferation in MEFs.
LPV sT per se induces transformation, and cooperates with LPV LT to
enhance transformation
Cells expressing LPV sT displayed morphological signs of
transformation and formed tight groups of cells (Fig. 3A). Fur-
thermore, the morphology of MEFs expressing both sT and LT
closely resembled the morphology observed in LPV.ER expressing
cells (Fig. 3A, compare to Fig. 1A). Thus, we next assessed the
capacity of LPV sT and LT to induce cell transformation. We per-
formed low serum and soft agar transformation assays with MEFs
expressing sT or LT, using wt MEFs as controls. While wt MEFs
ceased to proliferate in low serum conditions, sT-expressing MEFs
showed continuous cell proliferation (Fig. 4A). Surprisingly,
although LT induced proliferation of MEFs in the presence of 10%
serum (Fig. 3B), it failed to do so in media containing 1% serum
(Fig. 4A). Thus, LPV sT, but not LPV LT, allows MEFs to grow in low
serum conditions.
Next we performed soft agar assays to determine the ability of
sT and LT to allow MEFs to grow in anchorage independent con-
ditions. As expected, wt MEFs failed to proliferate in soft agar and
remained as single cells, while LPV.ER expressing MEFs readily
formed large soft agar colonies (Fig. 4B and C, see also Fig. 1D). The
performance of LPV LT and sT promoting growth in soft agar was
similar to their behavior in low serum conditions: While LT was
unable to support colony formation, MEFs expressing sT formed
colonies in soft agar (Fig. 4B and C). However, the size of colonies
induced by sT was signiﬁcantly smaller than the size of colonies
formed after LPV.ER expression (Fig. 4B and C). Indeed, theFs expressing different components of LPV.ER. Plating and manipulation of the cells
is of MEFs stably expressing LPV proteins. Pools of cells expressing different LPV
e number of cells was monitored every two days (Materials and methods). Each data
of each cell type. (C) Beta-galactosidase staining to determine senescence in MEFs
. The experiment was performed in triplicates and a representative image is shown.
xpressing MEFs and not in control MEFs.
Fig. 4. LPV sT is necessary and sufﬁcient to transform MEFs. (A) Growth in low serum of MEFs expressing LPV LT and sT, on their own or in combination. Cells were plated
and counted as described (Fig. 3B, Materials and methods). While wt MEFs and LPV LT MEFs ceased to proliferate, MEFs expressing LPV sT -by itself on with LT- proliferated
continuously. (B) Soft agar formation induced by LPV products. LPV ER and sT were able to induce colonies in soft agar, but not LT. (C) Box plots showing the size distribution
of colonies for each cell type. Size was determined from images taken from each colony, as described in Materials and methods, also Fig. 1D. Box plots showing the size
distribution of colonies for each cell type were prepared using R programming. Each box plot is divided into four quartiles, the thick line in the middle of the box represents
the median for the sample. Signiﬁcance testing was performed by wilcox test using R programming. The size of colonies present in LPV LT expressing MEFs was not
signiﬁcantly different than that observed in wt MEFs (p value 0.36). MEFs expressing either LPV.ER, sT, or LT plus sT formed colonies in soft agar at a signiﬁcantly larger rate
(p value«0.05). LPV sT expressing MEFs induced soft agar colonies of larger size than those formed by wt MEFs or LPV LT MEFs (p value¼0.0002), but the colonies were
signiﬁcantly smaller than those formed upon LPV.ER expression (p value¼0.02). Interestingly, co-expression of LPV LT and sT in trans resulted into signiﬁcant increase in soft
agar colonies with similar size to those found upon LPV.ER expression (p value¼0.622).
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niﬁcantly larger size than those observed in cells expressing either
oncogene independently (Fig. 4B and C). These results indicate
that LPV sT is sufﬁcient to induce transformation of MEFs, as
determined by low serum and soft-agar assays. However, a com-
plete recapitulation of the phenotype induced by LPV.ER requires
additional contribution/s by LPV LT.
LPV LT0 induces growth arrest in MEFs
As MEFs expressing LPV.ER also expressed LT0, we tested the
contributions of LPV LT0 to cell proliferation and immortalization.
In contrast to the cell expressing LT or sT, MEFs expressing LPV LT0
alone underwent growth arrest, displayed an enlarged morphol-
ogy (Fig. 3A), and failed to reach conﬂuency (Fig. 3A and B). LT0-
expressing cells failed to produce signs of senescence when tested
by β-galactosidase assay staining (data not shown). The results,
indicating that expression of LT0 produces growth arrest, were
surprising, as LT0 contains the LXCXE motif and thus should be able
to interact with and disrupt the RB family of proteins, an action
that normally results in cell cycle progression and cell prolifera-
tion. Therefore, we generated a LT truncation mutant (N200),
which shares the ﬁrst 200 amino acids with LT and LT0 but lacks
the unique LT0 C-terminus region (Fig. 2C). N200 contains the J
domain and LXCXE motif, and is thus expected to interact with the
RB proteins. The expression of N200 was conﬁrmed by western
blot analysis (Fig. 2E). In contrast to LT0-containing cells, MEFsexpressing N200 continue proliferating at similar rates to those
observed in LT-expressing MEFs (Fig. 3A and B). These results
indicate that LT0 possesses additional function/s within its C-
terminus unique region, linked to either prevent proliferation or
to inhibit cell growth.
Differential effects of the LPV.ER products on the RB pathway
The transformation abilities of SV40.ER are mostly attributed to
the LT-mediated inhibition of two major growth suppressive
pathways, RB/E2F and p53. SV40 LT interacts with all three
members of the RB family and induces disruption of the pRB/E2F
repressor complexes. While LT expression does not change pRb
levels signiﬁcantly, it induces proteosomal degradation of p130
and results in increased p107 protein levels (Stubdal et al., 1996;
Zalvide and DeCaprio, 1995). A signiﬁcant increase in E2F target
gene expression results from the inhibition of pRBs by LT (Rathi et
al., 2009), inducing cell proliferation.
We ﬁrst assessed the status of the retinoblastoma proteins
p107 and p130 in MEFs expressing LPV.ER or its different com-
ponents. In a similar way to SV40 LT, we found that the LPV.ER
induced a decrease in p130 and an increase in p107 protein levels,
as determined by western blot analysis (Fig. 5A). In addition, real-
time PCR analysis of MEFs expressing either LPV.ER or LPV LT
showed at least a 2-fold upregulation of E2F target genes (Fig. 5B)
in comparison to wt controls. We conclude that LPV LT blocks RB
tumor suppressors and elevates E2F-dependent transcription.
Fig. 5. Interaction of LPV products with the RB/E2F pathway. (A) Western blot
analysis of p130 and p107 proteins in MEFs expressing different LPV products.
SV40.ER-expressing MEFs were used as positive control. GAPDH was used as
loading control. (B) Real-time PCR analysis for canonical E2F target genes using
gene speciﬁc primers. The gene expression levels are represented relative to the
corresponding expression levels in wt MEFs, and Rpl5 expression levels were used
for cDNA normalization. The error bars represent standard deviation; within each
sample, each gene was analyzed in quadruplicate.
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and robust proliferation, we found that sT does not affect the RB/
E2F pathway signiﬁcantly. On one hand, sT neither decreased p130Fig. 6. Differential effects of LPV products on the tumor suppressor p53. (A) Evaluation
time PCR analysis of p53 target genes in MEFs expressing different LPV products. The ta
MEFs were used as baseline control. (C) Differential interactions between LPV product
recognizing the different LPV products) and subsequent western blot analysis with an
(þAb) of anti-LPV J-domain antibody. Input (I), supernantant (S), immunoprecipitated
agent. Cells were treated with or without doxorubicin and the levels of p53 evaluated blevels nor raised p107 levels (Fig. 5A) and, on the other, sT only
induced a modest upregulation of E2F genes (Fig. 5B). These
results suggest that LPV sT might trigger pathways other than RB/
E2F to elicit cell immortalization and proliferation.
Finally, we found that LT0 was unable to efﬁciently disrupt the
RB/E2F pathway. While expression of LPV LT0 decreased p130
protein levels in a similar way to LPV LT, it did not increase p107
levels (Fig. 5A). Furthermore, E2F gene expression in LPV LT0-
expressing MEFs did not increase and was similar to the basal
levels observed in wt MEFs. In contrast, expression of the trun-
cation mutant N200 decreased p130 and increased p107 protein
levels in a similar way to LPV LT (Fig. 5A). These results suggest
that disruption of the RB pathway is absent or incomplete in LT0
and might contribute to explain why LT0 fails to elicit immortali-
zation and cell proliferation in MEFs. However, the incomplete
inhibition of the RB/E2F pathway observed in LT0-expressing MEFs
might be explained, at least in part, by the relatively low expres-
sion levels of LT0 protein observed in comparison to levels of N200
protein found in MEFs (Fig. 2E).
Interaction between LPV T antigens and p53
SV40 LT binds to p53 and blocks its transcriptional activity, and
through this process LT enhances the protein stability of p53 (An et
al., 2012). However, previous studies regarding LPV LT interaction
with p53 proved controversial (Kang and Folk, 1992; Symonds et
al., 1991), thus we analyzed the effects of LPV.ER products on p53
status.
We found increased levels of p53 in MEFs expressing LPV.ER or
LPV LT (Fig. 6A). Furthermore, the transcriptional levels of several
p53-target genes were not upregulated in cells expressing LPV LT
(Fig. 6B), suggesting that the p53 protein present in LPV.ER or LPV
LT-expressing MEFs is inactive. We then performed co-
immunoprecipitation analysis to determine if LPV LT binds p53
in MEFs expressing LPV.ER or LT. Protein extracts from different
MEF cells were immunoprecipitated using a monoclonal antibodyof p53 protein levels in various cell types as determined by western blot. (B). Real
rget genes were normalized against the Rpl5 gene and the expression levels in wt
s and p53 as revealed by Immunoprecipitation with Xt7 (anti J-domain antibody
ti-p53. Immunoprecipitations were carried out in the absence (Ab) or presence
complex (IP). (D) LPV sT prevents p53 up-regulation induced by a DNA damaging
y western blot. GAPDH was used as loading control.
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were analyzed by western blot using a p53-speciﬁc antibody.
Both LPV.ER or LT expressing MEFs contained high levels of p53,
which in both cases co-precipitated by the J-domain speciﬁc
antibody, suggesting the existence of a complex between LPV T
antigens and p53 (Fig. 6C).
The LPV LT0 product was also able to raise p53 levels (Fig. 6A),
but not to the extent observed with LPV.ER or LPV LT. However,
p53 seems to be activated and not neutralized by the expression of
LT0, as p53 target levels increased signiﬁcantly in MEFs containing
LT0 (Fig. 6B). This suggests that LT0 elicits an active p53 response
and is unable to block p53, and is consistent with the growth
arrest observed in MEFs expressing LT0. In a similar fashion, the
carboxy terminus of MCV LT has been shown to posses a growth
inhibitory function and its expression leads to upregulation of p53
target genes and cell cycle arrest (Cheng et al., 2013; Li et al., 2013).
As expected, we observed neither increased p53 protein levels
in MEFs expressing LPV sT (Fig. 6A), nor upregulation of p53 target
genes (Fig. 6B). Surprisingly, we found that not only sT does not
trigger a p53 response, but that, in addition, it seems to prevent
p53 activation.
First, the presence of sT in LT0-expressing cells eliminates the
surge in p53 levels observed upon LT0 expression alone (Fig. 6A).
Furthermore, the upregulation of p53 target genes observed after
LT0 expression is eliminated when sT is co-expressed (Fig. 6B). We
then decided to test the ability of LPV sT to prevent p53 activation
by the cytotoxic agent doxorubicin (adriamycin). Control MEFs and
those expressing LPV LT or LPV sT were treated with doxorubicin,
and the presence of p53 was monitored by western blot. Untreated
MEFs contained no detectable p53 unless expressing LPV LT. The
doxorubicin treatment increased p53 levels in wt MEFs, but the
increase in p53 was obliterated by LPV sT expression and not LT
expression (Fig. 6D). These results suggest that LPV sT is able to
prevent p53 activation.Discussion
Previous studies have shown that the early region of LPV is able
to cause transformation of hamster cell lines, as well as to induce
robust tumorigenesis in transgenic mice (Kang and Folk, 1992;
Chen et al., 1989; Chen and Van Dyke, 1991). However, no study
has evaluated the different oncoproteins encoded by the LPV.ER, or
their role and contribution to cell transformation. In this study, we
have uncovered novel splice products encoded by LPV.ER, and
have extended the current knowledge of their individual con-
tributions to cell transformation. At least four different splice
products are encoded by LPV.ER: large T antigen (LT), small T
antigen (sT), a large T antigen splice form (LT0, large T prime) and a
small T antigen splice form (sT0, small T prime). While we found
evidence for the presence of all four transcripts in LPV.ER-
expressing MEFs, we detected LT, sT and LT0 protein expression but
failed to detect sT0. This could indicate that either sT0 protein levels
were very low or that the protein product is highly unstable.
LPV.ER expression induced transformation in MEFs to similar
levels as that observed in MEFs expressing SV40.ER. Our results
also indicate that, like SV40 LT, LPV LT inhibits the RB/E2F and p53
tumor suppressor pathways, thus suggesting similarities between
the mechanisms of action used by both LT oncoproteins to control
cellular proliferation. However, further analysis of the contribu-
tions provided by other LPV oncoproteins showed major differ-
ences between the two systems. While SV40 LT was sufﬁcient to
induce transformation of MEFs in cell culture, LPV LT was able to
immortalize MEFs but failed to transform them. In addition, we
found that the roles of LPV sT and SV40 sT in cell immortalization
and transformation are remarkably different. In SV40, sTcooperates with LT to transform human ﬁbroblasts and enhances
the LT-transformation phenotype in cell culture, but its sole
expression in primary or immortalized cells fails to induce pro-
liferation and results in growth arrest (Andrabi et al., 2011). In
agreement, we found that expression of SV40 sT in primary MEFs
results in senescence but, in contrast, the expression of LPV sT is
sufﬁcient to immortalize and transform MEFs, and cells expressing
LPV sT managed to proliferate under low serum conditions. Fur-
thermore, expression of LPV sT induced the formation of colonies
in soft agar, but the presence of both sT and LT increased trans-
formation signiﬁcantly. These results suggest that LPV sT is sufﬁ-
cient to induce immortalization and transformation in MEFs, but
cooperation with LPV LT is required to fully recapitulate the
transformation observed in LPV.ER expressing cells.
On one hand, we found that LPV sT is unable to degrade p130
or increase the transcriptional activity of E2F genes. On the other,
albeit lacking p53-binding domains, sT is able to prevent the
activation of p53 triggered by LT0 expression and/or by a DNA
damaging agent. Murine polyomavirus sT also seems to posses a
p53-supressing activity (Moule et al., 2004), although induction of
cell death by MuPyV sT is independent of the status of p53 (Pores
Fernando et al., 2015). These results suggests that LPV sT uses
pathways other than RB/E2F and p53 to elicit cell proliferation and
transformation.
To date, the only other polyomavirus sT shown to posses
transforming properties is encoded by MCPyV (DeCaprio and
Garcea, 2013; Shuda et al., 2011). However, in this case the
transformation was observed in immortalized cell types, thus it is
not clear if other factors are needed to contribute to cell immor-
talization prior to MCPyV sT action to elicit transformation. Other
than LPV sT, no other polyomavirus sT has been shown to
immortalize or transform primary cells in culture.
Many of the biological activities of sT are attributed to its
interactions with the protein phosphatase 2A (PP2A) protein
complex. An amino acid sequence comparison between homo-
logous sT proteins from different polyomaviruses shows high
conservation of the Hsc70 interacting J-domain HPD motif and
PP2A interacting motifs. However, major differences have been
observed regarding the mode of interaction. For instance, the sT
proteins from SV40, MuPyV and MCPyV all bind to PP2A, but while
SV40 sT oncogenic activity depends upon its inhibition of PP2A
mediated dephosphorylation of Akt, transformation mediated by
MCPyV sT is independent of PP2A interaction (Shuda et al., 2011).
Instead MCPyV sT bypasses the Akt-mTOR pathway and increases
phosphorylation of 4E-BP1, a cap-dependent translation regulator
(Shuda et al., 2011). In contrast, SV40 sT induces depho-
sphorylation of 4E-BP1 via Akt-mTOR signaling. Therefore, while
sT products from different polyomaviruses might disrupt the same
cellular pathways, their effects might vary considerably. Investi-
gating the transcriptional proﬁles of cells expressing LPV sT should
yield novel ways to approach cell transformation.Conclusions
The comparative study of homologous oncoproteins from dif-
ferent polyomaviruses has helped us to identify their molecular
targets and cell/tissue type speciﬁc roles. To date, only one poly-
omavirus sT (MCPyV sT) has been shown to transform cells in
culture by itself. We now report that LPV induction of tumor-
igenesis proceeds in different ways than previously suspected, and
that the small T antigen of LPV is necessary and sufﬁcient to
immortalize and transform primary MEFs in cell culture.
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Cell culture
Mouse embryonic ﬁbroblasts (MEFs) were routinely grown in
Dulbecco's modiﬁed Eagle's medium (DMEM; GIBCO) supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin. Wild-type (wt) MEFs were generated from E13.5 old
mouse embryos as previously described (Markovics et al., 2005).
When indicated, wt MEFs, LPV sT- and LPV LT-expressing MEFs
were treated with doxorubicin at 1 mM ﬁnal concentration for 18 h.
After treatment, cells were collected by trypsinization and protein
extracts were prepared for western blot analysis.
Cloning and vectors
The LPV.ER, LT cDNA, LT0 cDNA and N200 cDNA were inserted
into pLenti6.3-Blasticidin (Invitrogen) vectors by TOPO cloning
following the manufacturer's guidelines. LPV sT cDNA and also
LPV.ER were inserted into pBABE-puromycin using Gateway
cloning technology (Invitrogen), following the manufacturer's
guidelines. Total RNA from MEFs expressing LPV.ER was used to
prepare cDNA, and primers speciﬁc for the 50 and 30 end of the ER
were used to amplify the LPV LT and LPV LT0 cDNAs via PCR. The
PCR products were separated through 1% agarose gel and the
bands corresponding to LT and LT0 cDNAs were gel puriﬁed with
the Wizard SV gel puriﬁcation kit (Promega). The sequence of each
isolated DNA was veriﬁed and then inserted into pLenti6.3 vector
via TOPO cloning (Invitrogen). All the resulting constructs were
veriﬁed by sequencing.
Production and transduction of retrovirus and lentivirus
The packaging cell lines Phoenix-eco and 293FT were used to
produce retroviruses and lentiviruses, respectively. Transfections
were performed using lipofectamine (Invitrogen) following the
manufacturer's guidelines. MEFs were grown to 60–70% conﬂuency
and infected twice, every 24 h, with the retrovirus- or lentivirus-
containing media supplemented with 8 μg/ml polybrene. Virus-
containing media was replaced with regular media 24 h after
infection, and the corresponding selection with puromycin (3 μg/
ml) or blasticidin (3 μg/ml) was carried out for 5 days.
Western blots
Protein extractions and western blot analysis were performed
with standard methods. The following primary antibodies were
used: PAb416, PAb419 and PAb901 (monoclonal antibodies recog-
nizing SV40.ER products; (Tevethia et al., 1997; Harlow et al.,
1981)); p107 (Santa Cruz sc-318); p130 (Santa Cruz sc-317x); p53
(Santa Cruz sc-6243 HRP) and p21 (Santa Cruz sc-471). Mono-
clonal antibody Xt7 was raised by priming mice with recombinant
HPyV10 sT fused to maltose binding protein followed by boosting
with His-tagged recombinant HPyV10 J-domain. Hybridomas were
generated and screened as described (Pastrana et al., 2010). Vali-
dation experiments revealed that Xt7 cross-reacts with the J-
domain of a wide variety of polyomavirus LT proteins, including
LPV. Antibody characteristics are posted at http://home.ccr.cancer.
gov/Lco/BuckLabAntibodies.htm. After incubation with appro-
priate HRP-conjugated secondary antibodies, speciﬁc proteins
were detected by chemiluminescence (Luminata Forte, Millipore).
Reverse transcription PCR (RT-PCR) analysis
cDNAwas synthesized from total RNA using superscript II reverse
transcriptase (Invitrogen). PCR with GoTaq polymerase (Promega)was performed using equal amounts of cDNA from different samples
and gene speciﬁc primers. The PCR primers used were: Set A (50-
ACCATGGACCAAACGCTGTCTAAG-30 and 50-TTACATTTGTTCTTCAATT-
ACAATTCC-30) and Set B (50-ACCATGGACCAAACGCTGTCTAAG-30 and
50-AAAGCTGGGTCTTAGAATCCCAGTT-30).
Real-time PCR
Total RNA was isolated from approximately 1107 cells using
the Qiagen RNeasy mini kit, following the manufacturer's
instructions and including the DNase-in column treatment. Total
RNA (1 μg) was used to perform reverse transcription as pre-
viously described (Chong et al., 2009). Real-time semi-quantitative
PCR was performed using Maxima SYBR Green (Thermo Scientiﬁc)
in a 7300 Real-time PCR system (Applied Biosystems) with gene
speciﬁc primers as previously described (Chong et al., 2009). Each
reaction was performed in quadruplicate and the endogenous
values of Rpl5 within each cDNA were used to normalize the
samples.
Transformation assays
Soft-agar assay
1.6104 exponentially growing cells were plated in 0.33%
noble agar in duplicates. About 0.5 ml of MEF media was added on
top of the agar layer every 3–4 days to prevent it from drying.
Colonies were counted after 3–4 weeks of plating by the following
method: each plate was divided into 4 quadrants, and movies of
colonies formed in each quadrant were recorded using the ZEN
software package from ZEISS corporation. Each movie would
capture colonies growing in the different layers of agar, and the
size of colonies at 21 days was calculated by determining the area
under the curve using the same software. A wilcox statistical test
(wilcox.test) in R (http://www.r-project.org/) was used to calculate
whether variations between populations were signiﬁcant. All
experiments were performed in duplicate.
Growth in low serum
5103 cells were seeded into 12 well plates in normal serum
media containing 10% FBS. After 24 h, the cells were washed
3 times with PBS and low serum media with 1% FBS was added.
Two wells per cell type were trypsinized every two days and the
cells were counted using a hemocytometer.
Proliferation assays
Growth curve
Each well within 6 well plates received 2104 cells of different
cell types, and two wells per cell type were counted every 48 h
using a hemocytometer to generate proliferation curves.
Senescence assay
Wild type MEFs were infected with retroviruses containing
either either empty vector or SV40 sT cDNA. Cells were seeded into
6 well plates after 5 days of puromycin (3 μg/ml) selection. Beta-
Galactosidase (β-Gal) staining was performed as previously
described (Gupta et al., 2015). Brieﬂy, cells were washed with PBS
and ﬁxed with 2% formaldehyde plus 0.2% glutaraldehyde for
5 minutes at room temperature. Cells were then washed with PBS
and incubated overnight, at 37 °C with fresh β-Gal staining solution
(Bluo-Gal, halogenated-indoyl-beta-D-galactosidase, Invitrogen).
Blue staining was monitored the next day by light microscopy, and
all the images were taken at same magniﬁcation.
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